Affinity DataKi: 0.00100nMAssay Description:Inhibition of recombinant JAK2Checked by AuthorMore data for this Ligand-Target Pair
Affinity DataKi: 0.00500nMAssay Description:Inhibition of recombinant JAK3Checked by AuthorMore data for this Ligand-Target Pair
Affinity DataKi: 0.00500nMAssay Description:Inhibition of recombinant JAK3Checked by AuthorMore data for this Ligand-Target Pair
Affinity DataKi: 0.0450nMAssay Description:Binding affinity was determined against human thrombinMore data for this Ligand-Target Pair
TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 0.100nMAssay Description:Inhibitory activity of the compound against HIV-I protease was determinedMore data for this Ligand-Target Pair
Affinity DataKi: 0.100nMAssay Description:Binding affinity was determined against human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 0.120nMAssay Description:Binding affinity was determined against human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 0.300nMAssay Description:Binding affinity was determined against human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 0.380nMAssay Description:Binding affinity was determined against human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 0.5nMAssay Description:Inhibition of JAK2 by radiometric assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.600nMAssay Description:Inhibition of JAK2 by radiometric assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.800nMAssay Description:Inhibition of JAK2 by radiometric assayMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 1nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 1nMAssay Description:Inhibition of JAK2 by radiometric assayMore data for this Ligand-Target Pair
Affinity DataKi: 1nMAssay Description:Inhibition of JAK2 by radiometric assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.10nMAssay Description:Binding affinity was determined against bovine thrombin.More data for this Ligand-Target Pair
Affinity DataKi: 1.5nMAssay Description:Binding affinity was determined against bovine thrombin.More data for this Ligand-Target Pair
Affinity DataKi: 1.60nMAssay Description:Inhibition of JAK2 by radiometric assayMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 2nMAssay Description:Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 2nMAssay Description:Inhibition of JAK2 by radiometric assayMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 2nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 2nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 2.80nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 3nMAssay Description:Inhibition of JAK2 by radiometric assayMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 3nMAssay Description:Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 3.30nMAssay Description:Binding affinity was determined against human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 3.80nMAssay Description:Binding affinity was determined against human thrombinMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 4nMAssay Description:Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 4nMAssay Description:Inhibition of JAK2 by radiometric assayMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 4nMAssay Description:Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting methodMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 5nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 5nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 5nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 5nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 6nMAssay Description:Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting methodMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 6nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 6.5nMAssay Description:Binding affinity was determined against bovine thrombin.More data for this Ligand-Target Pair
Affinity DataKi: 7nMAssay Description:Inhibition of JAK2 by radiometric assayMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 7nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 7nMAssay Description:Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 8nMAssay Description:Binding affinity was determined against human thrombinMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 8nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 8nMAssay Description:Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting methodMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 9nMAssay Description:Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting methodMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 9nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetMast/stem cell growth factor receptor Kit(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 9nMAssay Description:Displacement of [33P]ATP from human recombinant c-KIT domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 9nMAssay Description:Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 15 mins in presence of [33P-ATP] by liquid scintillation counting methodMore data for this Ligand-Target Pair
TargetMast/stem cell growth factor receptor Kit(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 10nMAssay Description:Displacement of [33P]ATP from human recombinant c-KIT domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Vertex Pharmaceuticals
Curated by ChEMBL
Vertex Pharmaceuticals
Curated by ChEMBL
Affinity DataKi: 10nMAssay Description:Displacement of [33P]ATP from human recombinant FLT3 domain after 20 mins by scintillation countingMore data for this Ligand-Target Pair
Affinity DataKi: 11nMAssay Description:Binding affinity was determined against human thrombinMore data for this Ligand-Target Pair